Aprea Therapeutics Inc.

APRE | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.74

-$0.02 (-2.62%)

At close: Sep 21, 2026, 4:00 PM ET

$0.80

+$0.06 (+8.11%)

After-hours: Sep 21, 2026, 7:50 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.62%

(1D)

Rating

Updated: Aug 27, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $9.13M

1D Range

0.73 0.76

52W Range

0.55 1.69

Valuation (TTM)

PE -0.57

PB 0.24

EV/EBITDA 2.61

Valuation (NTM)

Forward PE N/A

Forward PEG -0.51

Price Target $2.10

Cash Flow

FCF Yield -133.5%

SBC Adj. FCF Yield -138.2%

SBC Impact -3.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -90.4% | 12.5%

Dil EPS 3Y | 5Y 39.3% | 55.2%

FCF 3Y | 5Y 5.8% | 25.7%

Returns

ROA -29.1%

ROE -46.7%

ROIC -33.7%

Financial Health

Net Cash

$41.23M

Current Ratio 13.55

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on mo...

Sector Healthcare

Industry Biotechnology

Employees 8

IPO Date Oct 2, 2019

Website www.aprea.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$2.10

Upside

+183.78%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞